Novo Nordisk says it filed lawsuits against multiple medical spas, weight loss clinics and compounding pharmacies for allegedly selling unauthorized versions of the drugmaker's popular medicines Ozempic and Wegovy.
Novo Nordisk is the sole patent holder of semaglutide and does not sell the ingredient to outside entities, raising questions about what is actually being sold to consumers.
The company has initiated five lawsuits, which were submitted in federal courts in New York, Texas, Florida and Tennessee, said Novo Nordisk spokesperson Allison Schneider.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst saysThe hit Wegovy weight-loss drug is on track for sales of over $4 billion this year in the U.S. alone, despite its manufacturer Novo Nordisk struggling to...
Lire la suite »
Ozempic users spark spike in ER visits: Shocking new side effectsThis celebrity-hyped injectable could cause cancer, blurred vision, pancreatitis, and gallstones — so is it really worth shooting your shot?
Lire la suite »
Hold Ozempic Before Surgery to Optimize Patient Safety?Holding Ozempic before elective surgery — and if so, for how long — remains largely a judgment call at this point. Official guidance on best practices has not yet caught up to surging popularity of this and other GLP-1 agonists for weight loss.
Lire la suite »
Company Behind Ozempic Cracks Down on CopycatsThe drugmaker is suing several medical spas, weight-loss clinics and wellness clinics for allegedly offering custom-made versions of Ozempic.
Lire la suite »
32 Wild And Hilarious Things People Actually Tweeted This Month So Far'Diet Coke...nature's Ozempic.'
Lire la suite »